A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ADX-850 in Participants With Hypertension
Latest Information Update: 14 Nov 2024
At a glance
- Drugs ADX 850 (Primary)
- Indications Hypertension
- Focus Adverse reactions; First in man
- Sponsors ADARx Pharmaceuticals
Most Recent Events
- 12 Nov 2024 Planned number of patients changed from 72 to 120.
- 12 Nov 2024 Planned End Date changed from 30 Jun 2026 to 30 Sep 2026.
- 23 Apr 2024 Status changed from not yet recruiting to recruiting.